Quantcast

Latest Tenofovir Stories

2010-07-26 07:30:00

TITUSVILLE, N.J., July 26 /PRNewswire/ -- Tibotec Pharmaceuticals today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TMC278 (rilpivirine), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), being studied for once-daily use with other antiretroviral agents in treatment-naive HIV-1-infected adults. If approved, TMC278 will be the third anti-HIV compound to be introduced by Tibotec Pharmaceuticals. The...

2010-07-22 07:30:00

VIENNA, July 22 /PRNewswire/ -- Tibotec Pharmaceuticals announced today results from two pivotal Phase 3, double-blind, randomized clinical trials comparing the efficacy, safety and tolerability of its investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine) versus efavirenz (EFV), each administered once daily with a nucleoside/nucleotide background regimen in treatment-naive, HIV-1-infected adults. These global trials, known as ECHO and THRIVE, reached...

2010-07-19 15:31:00

CAPRISA 004 trial shows moderate protection against transmission of virus JOHANNESBURG and WASHINGTON, July 19 /PRNewswire-USNewswire/ -- Results of an advanced clinical trial of an antiretroviral-based microbicide candidate are being announced at the International AIDS Conference in Vienna, Austria. The CAPRISA 004 trial, which tested the safety and effectiveness of 1% tenofovir gel among nearly 900 women at two sites in South Africa, found that using the gel before and after sex provided...

2010-07-19 15:10:00

WASHINGTON, July 19 /PRNewswire-USNewswire/ -- USAID Administrator Rajiv Shah released the following statement on today's historic CAPRISA 004 trial results: (Logo: http://photos.prnewswire.com/prnh/20091022/USAIDLOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20091022/USAIDLOGO) USAID is proud to be the major funder of the first-ever proof of concept that a microbicide can effectively and safely reduce the transmission of HIV from men to vulnerable women. An achievement of this...

2010-07-19 13:55:00

VIENNA, July 19 /PRNewswire-USNewswire/ -- "This is a historic day for HIV prevention research. The CAPRISA 004 results are the first clinical evidence that a microbicide gel can help to prevent sexual transmission of HIV infection," said AVAC Executive Director Mitchell Warren, reacting to the results of the landmark microbicide trial presented today at the International AIDS Conference in Vienna. "We believe that the most responsible plan of action now is to quickly and efficiently...

2010-06-17 06:00:00

HAIKOU, China, June 17 /PRNewswire-Asia/ -- Kun Run Biotechnology, Inc. (the "Company" or "Kun Run") (OTC Bulletin Board: KURU), a leading bio-pharmaceutical company in China focusing on manufacturing and sales of peptide-based and small molecule drugs, today announced that they have obtained the manufacturing approval for Entecavir from the China State Food and Drug Administration (SFDA). Entecavir is an oral antiviral drug used in the treatment of Hepatitis-B infection. It works by...

2010-06-02 07:00:00

WALTHAM, Mass., June 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of HIV, Gilead and Tibotec (a wholly owned subsidiary of Johnson & Johnson) remain on track to launch three novel treatment options in the next two years - Gilead's Quad (a four drug, one pill, once-daily, regimen), Tibotec's rilpivirine and Gilead/Tibotec's rilpivirine/emtricitabine/tenofovir...

2010-05-24 13:19:33

New research presented at International Microbicides Conference Their scientific methods may have been quite different, but their conclusions were not. In asking whether drug resistance could be a problem if antiretroviral (ARV) drugs become a mainstay for HIV prevention, the two studies "“ one involving a mathematical model and the other assays of cells and tissue "“ arrived at the same answer. Resistance could happen if people who are unknowingly already infected use the...

2010-05-13 07:30:00

RESEARCH TRIANGLE PARK, N.C., May 13 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the commencement of a first-in-human study of CMX157, a novel lipid conjugate of the nucleotide tenofovir with in vitro activity against both tenofovir-sensitive and tenofovir-resistant human immunodeficiency virus (HIV). CMX157 has the potential to increase efficacy and decrease toxicity as compared to tenofovir, and may enable...

2010-01-04 08:28:00

WALTHAM, Mass., Jan. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in 2018, the fixed dose coformulation of Tibotec's* rilpivirine and Gilead's Truvada will achieve blockbuster sales of more than $2 billion in the HIV drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The Pharmacor finding from the topic entitled Human Immunodeficiency Virus...


Word of the Day
siliqua
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'
Related